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 Abstract
 Background/Aims: Since detection of the prion protein gene  (PRNP) more than 30 mutations 
have been discovered. Some have only been found in single case reports without known in-
trafamilial accumulation or neuropathological proof so that the causal connection between 
mutation and disease could not be proved. Those patients often present atypical clinical phe-
notypes, and it is not unusual that they are classified as diseases other than Creutzfeldt-Jakob 
disease (CJD).  Methods: Cases of suspected CJD have been reported to the national reference 
center for prion diseases. Clinical and diagnostic data were collected, and a classification of 
definite, possible or probable prion disease was made. Molecular analysis of  PRNP was per-
formed by capillary sequencing.  Results: We have described 4 cases with atypical clinical and 
diagnostic findings and unknown mutations in  PRNP  so far.  Conclusion: Three patients ful-
filled the criteria of probable CJD, and 1 patient fulfilled the criteria of possible CJD but the 
clinical picture in none of the patients was typical CJD; hence, it remained questionable wheth-
er the mutations were causal of the disease.  Copyright © 2013 S. Karger AG, Basel
 Introduction
 The aggregation of the pathological prion protein (PrP Sc ) is the cause of prion diseases 
like Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI) and Gerstmann-Sträussler-
Scheinker syndrome (GSS), whereby the familial/genetic CJD (gCJD), FFI and GSS are caused 
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by an autosomal-dominant mutation in the prion protein gene  (PRNP) . More than 30  PRNP 
mutations have been reported so far. Frequent mutations in gCJD are the E200K mutation, 
which is widespread in Slovakia and in Libyan Jews, the V210I mutation in Italy, furthermore 
insert mutations in the UK and Germany as well as the E196K mutation in Germany  [1–5] . FFI 
is caused by the D178N mutation in combination with methionine at codon 129 of the  PRNP 
 [6] . For GSS several mutations exist such as P102L, P105L, A117V, F198S, Q217R, Q212P or 
D202N  [7–13] , and the clinical phenotype is typically characterized by a long disease duration 
and prominent ataxia at onset. In patients with new  PRNP mutations, the causal link is 
substantiated by intrafamilial inheritance of mutations with more than 1 disease-affected 
patient and/or detection of PrP Sc  in the brain. In many cases where mutations were reported 
only in single patients without any positive family history of prion disease or neuropatho-
logical examination, the responsibility of the mutation for disease development is likely but 
remains uncertain. In 4 patients examined here, the genetic testing revealed mutations which 
have not been reported in the literature before and could not be found in  PRNP sequencing 
series in CJD patients or healthy controls either. The disease phenotypes of these patients are 
discussed in the paper.
 Methods
 Suspected CJD cases in Germany have been reported to the experts of the national reference center for 
prion diseases in Germany who support the onsite neurologists in the diagnosing process by evaluating and 
excluding potential differential diagnoses. CSF analyses for 14-3-3 protein were performed by Western blot, 
and tau protein was measured by ELISA as previously reported  [14, 15] . Standard measurements of CSF like 
cell count, protein, oligoclonal bands and antibodies against neurotropic viruses as well as polymerase chain 
reaction (PCR) were made according to standard procedures. Electro-encephalograms (EEGs) were clas-
sified by an experienced neurophysiologist after the criteria established by Steinhoff et al. [16] with detection 
of periodic sharp wave complexes as the typical picture of CJD  and MRI results were assessed by an experi-
enced neuroradiologist with regard to hyperintensities in sensitive sequences (diffusion-weighted imaging, 
fluid-attenuated inversion recovery, T2-weighted imaging) in basal ganglia and/or two cortical areas 
(temporal, occipital, parietal or insular)  [17, 18] . To assign the results to definite, possible or probable CJD, 
the diagnostic criteria of 2001 were used  [15] as the examined cases were classified before 2009 when a 
modification was established  [17] . Neuropathological analyses were not done. Genetic analyses were 
performed from blood samples after informed consent. In brief, genomic DNA was extracted and the coding 
region of  PRNP was amplified by PCR. Subsequently, the complete open reading frame of  PRNP was subjected 
to mutational screening by direct sequencing on an ABI 3130 Genetic Analyzer. The amino acid at codon 129 
in coupling with the mutation was determined by cloning as described. A revision of the literature (PubMed 
search) was performed. All patients/next of kin gave their informed consent prior to publishing the data and 
present images. All human studies have been approved by the ethics committee of the Georg August University 
in Goettingen and have been performed in accordance with the ethical standards laid down in the 1964 Decla-
ration of Helsinki.
 Results
 Case 1 – Q52P
 The first symptom of this 80-year-old female patient was a commotio cerebri because of 
collapse 7 years before the differential diagnosis of CJD was considered and caused by a trend 
toward epileptic seizures in the EEG, so the diagnosis of symptomatic epilepsy was made. The 
patient was placed on valproate treatment. In addition the diagnosis of polymyalgia was 
made because she suffered from pain in the shoulder, weight loss, visual disturbances, a high 
red blood cell sedimentation rate and an elevated rheumatoid factor. Five months later she 
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complained of vertigo, fatigue, exhaustion and ataxia, a rapidly progressive dementia, altered 
sleep-wake pattern and apraxia became evident. During the disease course, she suffered from 
3 grand mal epileptic attacks, whereby the physicians diagnosed a valproate encephalopathy 
and changed the medication to phenobarbital. Under this medication the EEG did not exhibit 
epileptic changes anymore, but severe changes of general activity were detected. A following 
EEG recording 1 month after the onset of the neurological syndrome revealed periodic sharp 
and slow wave complexes suggestive of CJD. Clinically she developed positive primitive 
reflexes, pyramidal signs, increased muscle tone and tremor. CSF analysis was negative for 
14-3-3 protein; tau protein was normal with 277 pg/ml. An MRI scan was not available. Her 
nutrition was supported by installation of a percutaneous endoscopic gastrostomy. She died 
7.5 years after the first episodes of vertigo and 7 years after the onset of ataxia. In her family 
no remarkable history of dementia or other neurodegenerative dis - eases existed. Direct 
sequencing of the  PRNP open reading frame revealed a Q52P mutation and heterozygosity for 
methionine and valine at codon 129. No autopsy was performed, and no other family member 
underwent genetic testing. 
 Case 2 – V203G
 A 74-year-old woman was hospitalized for clarification of an uncertain illness with 
dementia, cerebellar symptoms, apraxia, withdrawal and depression which had begun 6 
months before. Because she also had a breast cancer with widespread metastases, weight loss 
and autonomic dysregulation, she was diagnosed with a paraneoplastic syndrome at that 
time. Her examination at hospitalization revealed dementia, withdrawal, ataxia, positive 
primitive reflexes and sensory disturbance. The comprehensive laboratory tests were normal 
for all values. 14-3-3 protein was detected in the CSF and also an increased tau protein (6,332 
pg/ml, reference <1,300 pg/ml). The EEG displayed only general slowing of the basal activity 
and no episodes of triphasic waves, but the cerebral MRI scan presented cortical hyperinten-
sities in the occipital and temporal region ( fig. 1 ). She was discharged from the hospital with 
the diagnosis of paraneoplastic disease, but after tumor surgery no clinical improvement took 
a b
 Fig. 1. MRI of the patient in case 2. a Fluid-attenuated inversion recovery sequence with cortical hyperinten-
sities occipital on both sides. b Diffusion-weighted imaging sequence presenting cortical hyperintensities in 
the occipital and cingulate gyrus. 
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place. After 2 months she developed myoclonus and after 12 months she died in the stage of 
akinetic mutism. Direct sequencing of the  PRNP open reading frame revealed a T > G substi-
tution resulting in an amino acid change from valine to glycine at codon 203  PRNP (V203G) 
and homozygosity for valine at codon 129. The family history revealed no neurodegenerative 
disease in the relatives. No autopsy was performed, and no other relative underwent genetic 
testing.
 Case 3 – Q212H
 The first symptom of the 63-year-old female patient was a visual disorder. She repeatedly 
requested new glasses (4 times in 1 year) and also complained about diplopia, headache, 
weakness and coordination disturbance and slight memory deficits. Through the following 
months she developed developmental delay and ataxia. An MRI scan revealed a tumor in the 
medial sphenoid wing which was removed, and the histopathological analysis revealed a 
pituitary adenoma (prolactinoma). The neurological status a few days prior to surgery 
showed visual disturbances, extrapyramidal signs, hypesthesia, dysdiadochokinesia and 
global aphasia. Furthermore she was unable to walk. After surgery she developed a diabetes 
insipidus, which was treated successfully. On discharge she still presented with global aphasia 
(improved in comparison to the status before surgery), disorientation, concentration and 
attention disturbances, apraxia, pyramidal and extrapyramidal signs and incontinence, but 
her gait improved. In the next month she underwent intensive rehabilitation with a transient 
improvement of gait and orientation. One year later (2.5 years after onset of initial symptoms) 
she was rehospitalized due to a deterioration of her condition. She presented dementia and 
depression, progressive aphasia, visual disturbances, increased muscle tone apraxia, dystonia 
of the right arm (alien limb phenomenon), gait disturbances, postural instability and positive 
pyramidal signs. For the first time the differential diagnosis of a CJD was considered. The CSF 
analysis for 14-3-3 protein was negative, and tau protein was normal with 76 pg/ml. The EEG 
presented no triphasic waves and in the MRI scan only the residues of the surgery were seen, 
no hyperintensities in the cortex or the basal ganglia where detectable. The diagnosis of corti-
cobasal degeneration was made on clinical grounds. In the following 3 months the language 
production decreased to 1-word sentences, she presented rigidity, gripping reflex, dystonia 
of both arms and stereotypic movements. A further CSF analysis was again negative for 14-3-3 
protein; tau protein increased slightly to 114 pg/ml (normal value). The EEG presented an 
epileptic focus and was still negative for CJD-typical findings, also the MRI scan. Blood analysis 
for a mutation in the  PRNP revealed a G > C substitution resulting in an amino acid exchange 
from glutamine to histidine at codon 212 (Q212H). We also found a silent polymorphism at 
codon 179 (N179N) and homozygosity for methionine at codon 129. Five years after the first 
symptoms had occurred, she was akinetic and mute. Two years later she died. No autopsy was 
performed. The family history was negative for dementia and/or neurodegenerative disorder, 
and no genetic testing of other family members was performed.
 Case 4 – N173K
 A decline of a known coronary heart disease was the reason for hospitalizing this 
73-year-old male patient. During the hospital stay the physicians suspected a cognitive 
impairment and the Mini Mental State Examination revealed 17 of 30 points, which corre-
sponds to dementia. Subjective cognitive impairment had occurred 2 years before and he had 
difficulties to fall asleep and was agitated. Two months later his general condition deterio-
rated. He suffered from vertigo, multiple falls, ataxia and worsening of the previously described 
dementia. The patient presented myoclonic jerks so that the neurologist ordered a CSF 
analysis for 14-3-3 protein which was negative; tau protein was normal with 457 pg/ml, and 
he featured a slight dysfunction of the blood-brain barrier. The EEG presented a severe distur-
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bance of the normal function with some non-periodic triphasic waves. In the MRI scan an 
arachnoid cyst in the right hemisphere of the cerebellum and some white matter lesions in 
the cerebrum were detected, but no CJD-typical hyperintensities (fluid-attenuated inversion 
recovery and T2-weighted images available). Direct sequencing of the  PRNP gene open 
reading frame revealed a C > G substitution at codon 173 resulting in replacement of aspar-
agine by lysine (N173K) and heterozygosity at codon 129. Cloning experiments demonstrated 
coupling of the N173K mutation with valine. He died 4.6 months after the first hospitalization 
and 2.5 years after the first symptoms of cognitive decline. He did not undergo an autopsy. No 
information about the family history was available.
 Discussion
 Since starting the CJD surveillance system in Germany, 2,145 patients have undergone a 
genetic testing  [19] . The prevalence of genetic prion diseases in humans in the German popu-
lation is presented in  figure 2 . Seven percent of all CJD cases are linked to a mutation and 57% 
out of them are gCJD. All cases presented in this paper have not been classified as CJD in the 
first instance, although cases 1, 3 and 4 fulfilled the criteria of possible CJD and case 2 fulfilled 
the criteria of a probable CJD. Because of atypical clinical phenotypes only genetic testing led 
to the assumption that these patients might have been affected by a prion disease. In the 
absence of neuropathological analysis and genetic testing of relatives the link remains 
uncertain.  Table 1 presents a summary of the patients’ data. While the 4 mutations in this 
study have not been reported in the literature so far, other mutations in a similar region of 
the  PRNP have been observed before. At codon 203 another base exchange with a G-to-A 
substitution exists with changing valine to isoleucine (V203I). In the literature 2 patients 
presented this mutation. In 1 patient the V203I mutation in  PRNP was combined with homo-
zygosity for methionine  [20] and in another case the mutation was combined with heterozy-
gosity at codon 129  PRNP , whereby the mutation was linked to the valine allele  [21] . One of 
these patients underwent an autopsy and CJD could be proven  [21] . Another well-known 
mutation near V203G and V203I on  PRNP is the V210I mutation  [22] . It occurs worldwide and 
GSS
1%
FFI
2%
gCJD
4%
sCJD
93%
 Fig. 2. Prevalence of genetically transmitted prion 
disease in humans in the German population. sCJD = 
Sporadic Creutzfeldt-Jakob disease. 
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is definitely connected to gCJD  [23] . The Q212P mutation affects the same codon as the Q212H 
mutation and effects a substitution of glutamine by proline; hence, this mutation is linked to 
the GSS syndrome  [13, 24] . Two patients with this mutation have been reported so far. One 
patient underwent an autopsy and in the neuropathological examination he presented PrP Sc  
deposition in the brain, an abnormal PrP immunoblot and no spongiform degeneration  [13] . 
At codon 173 no other irregularity has been described before, but next to codon 173, at codon 
171, whereby its responsibility for causation of CJD could not be clarified yet. The N171S 
mutation was reported first in 1997 in a Brazilian family where 6 of 12 tested relatives were 
positive for the mutation and 5 presented signs of an illness, distributed over 3 generations. 
The prominent symptoms were different psychiatric features (depression, delusion, halluci-
nation, schizophrenia, schizoaffective disorders). Samaia et al.  [25]  summarized a new 
causally linked mutation with a psychiatric featured phenotype. In contradiction Tsai et al. 
 [26] tested a large group of patients (n = 234) with familial schizophrenia, non-familial schizo-
phrenia and healthy controls and did not find the N171S mutation in  PRNP ; nonetheless, an 
association between the mutation and the disease was not excluded by this analysis. The 
notion that N171S might be a non-pathogenic polymorphism has been reinforced by the fact 
 Table 1.  Summary of epidemiological data, clinical findings and results of diagnostic tests in the patients described in this paper
 Patient  Mutation/
 codon 129 
 Gender  Age
 years 
 Disease 
duration
 years 
 Clinical findings  14-3-3 
protein 
 Tau 
 protein
 pg/ml 
 EEG  MRI  Accompanying 
disease/differential 
diagnoses 
 1  Q52P; 
 MV 
 female  80  7.5  vertigo, fatigue, exhaustion, 
ataxia, dementia, day-night 
reversal, apraxia, grand mal 
epileptic attacks, paresis right 
arm, primitive reflexes,
 pyramidal signs, increased 
muscle tonus, tremor 
 –  277  –  Ø  Epilepsy,
 polymyalgia  
 2  V203G; 
 VV 
 female  74  1  dementia, apraxia, cerebellar 
symptoms, withdrawal, 
depression, primitive reflexes,  
sensory disturbance,
 myoclonus, akinetic mutism 
 +  6,332  –  +  breast cancer 
 3  Q212H; 
N179N; MM 
 female  63  7  visual disorder, diplopia, 
headache, weakness, 
dementia, developmental 
delay, multiple falls,
 dystonia, hypesthesia,
 dysdiadochokinesia, global 
aphasia, hemiparesis, apraxia, 
incontinence, dystonia (alien 
limb), positive Babinsky sign, 
depression, rigor, gripping 
reflex, mutism 
 –  114  –  –  prolactinoma, 
primary
 hyperpara-
thyroidism,
 corticobasal
 degeneration 
 4  N173K; MV  male  73  2.5  Dementia, vertigo, multiple 
falls, ataxia, myoclonus 
 –  457  –  –  Coronary heart 
disease, bypass 
 – = Negative; + = positive; Ø = not available. 
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that it was also found in healthy controls in  PRNP screening studies  [24, 27] . Appleby et al. 
[28] described an African-American family with the gCJD D178N-129V mutation in combi-
nation with the N171S polymorphism in 3 generations, which presented also prominent 
psychiatric symptoms. More speculative is a connection between the N173K mutation and 
the D178N mutation, which are only separated by 5 codons. In clinical appearance, the D178N 
mutation as well as the N173K mutation are accompanied by several sleeping abnormalities. 
Certainly the patient in case 3 is linked to the allele with valine at codon 129, whereby sleeping 
abnormalities in the D178N mutation are generally linked to methionine at codon 129 (lead 
to FFI) and are not typical of the valine-linked allele (lead to gCJD)  [29] . In the literature some 
more cases have been presented with uncommon mutations in  PRNP , atypical clinical course 
and without neuropathological proof of PrP Sc  – e.g. the D202G mutation with a disease 
duration of 16 years  [30] . In other cases neuropathological analyses and proof of PrP Sc  have 
been detected and the mutations could be linked to prion disease in defiance of atypical 
clinical phenotype or negative results in diagnostic tests – e.g. the S132I mutation in a 
62-year-old woman with a disease duration of 18 months and merely dementia as clinical 
signs, the G131V mutation in a 51-year-old man with 9 years of dementia and ataxia, the 
A133V mutation in a 63-year-old woman with prominent progressive supranuclear palsy 
syndrome, the P105S mutation in a 30-year-old woman with a disease duration of 10 years 
and symptoms of dementia, aphasia, parkinsonism and behavioural changes, further the 
R208H mutation in a 61-year-old man with a disease duration of 7 months with dementia, 
psychiatric symptoms and ataxia  [31–35] . Only very few patients with rare mutations 
presented myoclonic jerks, positive 14-3-3 protein detection in CSF, periodic sharp and slow 
wave complexes in the EEG or hyperintensities in the MRI scan. 
 Conclusion
 Mutations in  PRNP can produce diverse clinical phenotypes; that is why the patients 
described in this examination do not necessarily present the typical clinical CJD-syndrome. 
Moreover, in some cases the final diagnoses are still unexplained, although in patient 4 CJD is 
the most likely diagnosis and in case 2 no alternative diagnosis was suggested or supported 
by any diagnostic tests and/or clinical syndrome. The atypical clinical course and the long 
disease durations were the reasons for requesting a genetic test. Unfortunately no neuro-
pathological analyses are available for the considered patients and also no genetic testing in 
relatives was performed in order to prove inheritance and intrafamilial accumulation of the 
mutations. In other cases in the literature, where only single cases with new mutations and 
atypical clinical courses have been presented, the CJD diagnoses could be proven a few years 
later by a neuropathological analysis. For instance, the E196K mutation in  PRNP was reported 
the first time by Peoc’h et al.  [22] in 2000 and the proof of disease pathogenesis was performed 
11 years later with neuropathological verification and presentation of families with more 
than 1 affected relative  [5] . Another example is the T188K mutation, which was reported for 
the first time in 2000 by Finkh et al.  [36] , and the neuropathological evidence was provided 
in 2007 by Roeber et al.  [37] . Another way to verify the pathogenic role of such rare mutations 
could be the genetic testing of a healthy population. The description of the cases mentioned 
in this report can serve to detect future cases with these mutations in the clinical findings and 
results of the diagnostic tests, and there are some further examples of the wide spectrum of 
potential  PRNP mutation-mediated diseases. 
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